MetaCap

Structure Therapeutics Inc. ADR (GPCR)

NASDAQ: GPCRHealth CareBiotechnology: Pharmaceutical PreparationsUSD

16.13-0.99 (-5.78%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

GPCR stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$3.90
52-week range
16.06 – 94.90
Day range
16.08 – 17.08
Volume / Avg
786.13K / 1.18M
Beta
—

52-week range

$16.06$94.90

GPCR stock today

Shares of Structure Therapeutics (GPCR) finished lower on Nov 20 at $16.13, a drop of 5.78% or $0.99 per share, versus the S&P 500's 3.70% decline. At this level, GPCR sits near the bottom of its 52-week range of $16.06 to $94.90: 83.0% below the high, set on Dec 8, 2025 and 0.4% above the low. GPCR is down 76.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 53.0%.

Structure Therapeutics has posted a net loss over the last twelve months (EPS of -$3.90), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Structure Therapeutics

Company profile

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, an oral small molecule amylin receptor agonist that is in phase1 clinical trial for the treatment of obesity; ANPA-0073, an oral small molecule APJ receptor agonist; and LTSE-2578, an antagonist that targets lysophosphatidic acid 1 receptor, a G-protein coupled receptors implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of idiopathic pulmonary fibrosis.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Raymond C. Stevens Ph.D.
Headquarters
South San Francisco, CA
Employees
281
IPO year
2023

Financial highlights

Full financials

Structure Therapeutics reported a net loss of $141.2 million, compared with a loss of $122.5 million a year earlier. Diluted earnings per share came in at -$0.80.

Structure Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022
Revenue————
Growth————
Net income$-141.20M$-122.53M$-89.62M$-51.32M
EPS (diluted)$-0.80$-0.78$-0.81$-5.51

Analyst forecast

Forecast

Consensus (16 analysts)

strong_buy

Avg. price target

$104.86+550.09%

  • Strong buy 4
  • Buy 11
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $70.00High $145.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-0.66 vs $-0.51
Surprise
-29.41%

GPCR news

All GPCR news

Structure Therapeutics peers

Health Care sector
GPCR peer companies
CompanyPrice% ChgMarket capCompare
OPKOPKO Health Inc.1.57-2.48%$1.17Bvs GPCR
HROWHarrow Inc.30.41-5.35%$1.14Bvs GPCR
CMPSCOMPASS Pathways Plc American Depository Shares8.05-6.94%$1.14Bvs GPCR
AAPGAscentage Pharma Group International American Depository Shares11.97-3.78%$1.12Bvs GPCR
GHRSGH Research PLC17.53-5.55%$1.20Bvs GPCR
AMPHAmphastar Pharmaceuticals Inc.28.25+0.50%$1.20Bvs GPCR
MLYSMineralys Therapeutics Inc.13.66-3.53%$1.21Bvs GPCR
OCULOcular Therapeutix Inc.5.57-4.95%$1.23Bvs GPCR

Indexes, lists and sector

Structure Therapeutics stock FAQ

What is Structure Therapeutics's stock price today?

GPCR last traded at $16.13 as of Nov 20, 4:00 PM EST, down 5.78% on the day. Prices are delayed at least 15 minutes.

Who is Structure Therapeutics's CEO?

Dr. Raymond C. Stevens Ph.D. is the chief executive officer of Structure Therapeutics Inc. ADR, which has about 281 employees.

What is the GPCR 52-week high?

The 52-week high for GPCR is $94.90 and the 52-week low is $16.06. The stock is currently 83.0% below its high.

Compare GPCR